According to data compiled by Bloomberg, Endo Pharmaceuticals has completed six deals in the past five years, with an average size of $352.8m and a typical premium of 49%.
In May 2010, the company showed interest to acquire urologic lab services and devices provider HealthTronics for $223m.
Endo Pharmaceuticals also agreed to acquire US-based generic drug manufacturer Qualitest Pharmaceuticals in September 2010 for about $1.2bn from PE firm Apax Partners.
